Metformina Uxa (Metformin Hydrochloride)

Metformin acts primarily on the liver by inhibiting mitochondrial complex I, which suppresses gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK) in muscle and fat tissue, increasing glucose uptake and utilization. These combined actions lower circulating glucose without stimulating insulin secretion.

The dose of Metformina Uxa is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule; no fixed regimen is provided here.

Metformina Uxa is classified as a prescription‑only medication, and its safety in pregnancy or lactation should be evaluated by a qualified clinician. Generally, it may be used during pregnancy only when the potential benefit justifies the potential risk, and breastfeeding mothers should discuss alternatives with their doctor.

To request Metformina Uxa, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Metformina Uxa (metformin) belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike sulfonylureas, metformin does not stimulate insulin release, resulting in a lower intrinsic risk of hypoglycemia. It is often used as first‑line therapy because of its efficacy, weight‑neutral profile, and cardiovascular benefits.

Metformina Uxa should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Metformina Uxa is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets (or other oral dosage form) are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or chew the tablets unless specifically instructed.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition characterized by rapid breathing, muscle pain, and abdominal discomfort. Severe hypoglycemia can also occur, particularly when metformin is combined with insulin or sulfonylureas. Prompt medical attention is required if any of these symptoms arise.

Metformina Uxa is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and those with known hypersensitivity to metformin. Caution is also advised for individuals with significant hepatic disease, heart failure, or a history of lactic acidosis.